The regulation of microRNAs on chemoresistance in triple-negative breast cancer: a recent update

References

• Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24(9), 2206–2223 (2013).
   PubMed Web of Science ®Google Scholar
• Vallejos CS, Gómez HL, Cruz WR et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin. Breast Cancer 10(4), 294–300 (2010).
   PubMed Web of Science ®Google Scholar
• Arnedos M, Bihan C, Delaloge S et al. Triple-negative breast cancer: are we making headway at least? Ther. Adv. Med. Oncol. 4(4), 195–210 (2012).
   PubMed Web of Science ®Google Scholar
• Mayer IA, Abramson VG, Lehmann BD et al. New strategies for triple-negative breast cancer–deciphering the heterogeneity. Clin. Cancer Res. 20(4), 782–790 (2014).
   PubMed Web of Science ®Google Scholar
• Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 8, 1342 (2019).
   Google Scholar
• Romano G, Veneziano D, Acunzo M et al. Small non-coding RNA and cancer. Carcinogenesis 38(5), 485–491 (2017).
   PubMed Web of Science ®Google Scholar
• Chang S, Johnston RJ Jr, Frøkjaer-Jensen C et al. MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode. Nature 430(7001), 785–789 (2004).
   PubMed Web of Science ®Google Scholar
• Davis BN, Hilyard AC, Nguyen PH et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol. Cell 39(3), 373–384 (2010).
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415–419 (2003).
   PubMed Web of Science ®Google Scholar
• Blahna MT, Hata A. Regulation of miRNA biogenesis as an integrated component of growth factor signaling. Curr. Opin. Cell Biol. 25(2), 233–240 (2013).
   PubMed Web of Science ®Google Scholar
• Ding HX, Lv Z, Yuan Y et al. MiRNA polymorphisms and cancer prognosis: a systematic review and meta-analysis. Front Oncol. 8, 596 (2018).
   PubMed Web of Science ®Google Scholar
• Bach DH, Hong JY, Park HJ et al. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int. J. Cancer 141(2), 220–230 (2017).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Gebert LFR, Macrae IJ. Regulation of microRNA function in animals. Nat. Rev. Mol. Cell Biol. 20(1), 21–37 (2019).
   PubMed Web of Science ®Google Scholar
• Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 17(8), 523–531 (2010).
   PubMed Web of Science ®Google Scholar
• Amawi H, Sim HM, Tiwari AK et al. ABC transporter-mediated multidrug-resistant cancer. Adv. Exp. Med. Biol. 1141, 549–580 (2019).
   PubMed Web of Science ®Google Scholar
• Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160(3), 161–175 (1997).
   PubMed Web of Science ®Google Scholar
• Ford RC, Beis K. Learning the ABCs one at a time: structure and mechanism of ABC transporters. Biochem. Soc. Trans. 47(1), 23–36 (2019).
   PubMedGoogle Scholar
• Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum. Genom. 3(3), 281–290 (2009).
   PubMedGoogle Scholar
• Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580(12), 2903–2909 (2006).
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi T, Zhang L et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 370(1), 153–164 (2016).
   PubMed Web of Science ®Google Scholar
• Yamada A, Ishikawa T, Ota I et al. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res. Treat. 137(3), 773–782 (2013).
   PubMed Web of Science ®Google Scholar
• Guestini F, Ono K, Miyashita M et al. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 173(2), 275–288 (2019).
   PubMed Web of Science ®Google Scholar
• Britton KM, Eyre R, Harvey IJ et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 323(1), 97–105 (2012).
   PubMed Web of Science ®Google Scholar
• Sissung TM, Baum CE, Kirkland CT et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol. Biotechnol. 44(2), 152–167 (2010).
   PubMed Web of Science ®Google Scholar
• Oguri T, Bessho Y, Achiwa H et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 6(1), 122–127 (2007).
   PubMed Web of Science ®Google Scholar
• Fanini F, Fabbri M. MicroRNAs and cancer resistance: a new molecular plot. Clin. Pharmacol. Ther. 99(5), 485–493 (2016).
   PubMed Web of Science ®Google Scholar
• Yeh WL, Tsai CF, Chen DR. Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer. Stem Cell Res. Ther. 8(1), 177 (2017).
   PubMedGoogle Scholar
• Zuo J, Yu Y, Zhu M et al. Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation. Cancer Biomark 21(2), 383–392 (2018).
   PubMed Web of Science ®Google Scholar
• O'brien C, Cavet G, Pandita A et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 68(13), 5380–5389 (2008).
   PubMed Web of Science ®Google Scholar
• Zeng C, Fan D, Xu Y et al. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Biochem. Pharmacol. 174, 113795 (2020).
   PubMed Web of Science ®Google Scholar
• Bao L, Hazari S, Mehra S et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol. 180(6), 2490–2503 (2012).
   PubMed Web of Science ®Google Scholar
• Yi D, Xu L, Wang R et al. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1. Cell Biol. Int. 43(1), 12–21 (2019).
   PubMed Web of Science ®Google Scholar
• Simões-Wüst AP, Schürpf T, Hall J et al. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76(2), 157–166 (2002).
   PubMed Web of Science ®Google Scholar
• Campbell KJ, Dhayade S, Ferrari N et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 9(2), 19 (2018).
   PubMedGoogle Scholar
• Ozretic P, Alvir I, Sarcevic B et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int. J. Biol. Markers 33(1), 109–115 (2018).
   PubMed Web of Science ®Google Scholar
• Pan B, Yi J, Song H. MicroRNA-mediated autophagic signaling networks and cancer chemoresistance. Cancer Biother. Radiopharm. 28(8), 573–578 (2013).
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9(1), 47–59 (2008).
   PubMed Web of Science ®Google Scholar
• Liu X, Tang H, Chen J et al. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget 6(24), 20070–20083 (2015).
   PubMedGoogle Scholar
• Hou X, Niu Z, Liu L et al. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol. Lett. 17(1), 990–998 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Wei Y et al. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition. Sci. Rep. 5, 15424 (2015).
   PubMed Web of Science ®Google Scholar
• Ouyang M, Li Y, Ye S et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLOS ONE 9(5), e96228 (2014).
   PubMed Web of Science ®Google Scholar
• Perotti C, Liu R, Parusel CT et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res. 10(6), R94 (2008).
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad Sci. 1113, 202–216 (2007).
   PubMed Web of Science ®Google Scholar
• O'brien K, Lowry MC, Corcoran C et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6(32), 32774–32789 (2015).
   PubMed Web of Science ®Google Scholar
• Yao YS, Qiu WS, Yao RY et al. miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol. Rep. 33(5), 2504–2512 (2015).
   PubMed Web of Science ®Google Scholar
• Huang Z, Su GF, Hu WJ et al. The study on expression of CIAPIN1 interfering hepatocellular carcinoma cell proliferation and its mechanisms. Eur. Rev. Med. Pharmacol. Sci. 21(13), 3054–3060 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang YF, Li XH, Shi YQ et al. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Oncol. Rep. 25(4), 1091–1098 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang XW, Liu L, Zhang XZ et al. Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Exp. Ther. Med. 14(2), 1789–1794 (2017).
   PubMed Web of Science ®Google Scholar
• Wang XM, Gao SJ, Guo XF et al. CIAPIN1 gene silencing enhances chemosensitivity in a drug-resistant animal model in vivo. Braz. J. Med. Biol. Res. 47(4), 273–278 (2014).
   PubMed Web of Science ®Google Scholar
• Deng YW, Hao WJ, Li YW et al. Hsa-miRNA-143-3p reverses multidrug resistance of triple-negative breast cancer by inhibiting the expression of its target protein cytokine-induced apoptosis inhibitor 1 in vivo. J. Breast Cancer 21(3), 251–258 (2018).
   PubMed Web of Science ®Google Scholar
• Chen J, Shi P, Zhang J et al. CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by sponging miR-145 and regulating NRAS. Mol. Med. Rep. 25(2) (2022).
   Web of Science ®Google Scholar
• Tang X, Jin L, Cao P et al. MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget 7(17), 23668–23683 (2016).
   PubMedGoogle Scholar
• Wang S, Oh DY, Leventaki V et al. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett. 465, 12–23 (2019).
   PubMed Web of Science ®Google Scholar
• Ao X, Nie P, Wu B et al. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis. 7(11), e2463 (2016).
   PubMedGoogle Scholar
• Niu J, Xue A, Chi Y et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 35(10), 1302–1313 (2016).
   PubMed Web of Science ®Google Scholar
• Fang H, Xie J, Zhang M et al. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am. J. Transl. Res. 9(3), 953–961 (2017).
   PubMed Web of Science ®Google Scholar
• Chen L, Bourguignon LY. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol. Cancer 13, 52 (2014).
   PubMed Web of Science ®Google Scholar
• Luo LJ, Yang F, Ding JJ et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple-negative breast cancer. Gene 594(1), 47–58 (2016).
   PubMed Web of Science ®Google Scholar
• Körner C, Keklikoglou I, Bender C et al. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J. Biol. Chem. 288(12), 8750–8761 (2013).
   PubMed Web of Science ®Google Scholar
• Shen X, Lei J, Du L. miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC. Exp. Ther. Med. 19(1), 375–383 (2020).
   PubMed Web of Science ®Google Scholar
• Liu M, Gong C, Xu R et al. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2. Cell Mol. Biol. Lett. 24, 47 (2019).
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao A, Tan T et al. Overexpression of microRNA-620 facilitates the resistance of triple-negative breast cancer cells to gemcitabine treatment by targeting DCTD. Exp. Ther. Med. 18(1), 550–558 (2019).
   PubMed Web of Science ®Google Scholar
• Xia H, Hui KM. MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 19(11), 723–730 (2012).
   PubMed Web of Science ®Google Scholar
• Du C, Wang Y, Zhang Y et al. LncRNA DLX6-AS1 contributes to epithelial–mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p/paxillin axis. Cell Transplant. 29, 963689720929983 (2020).
   PubMed Web of Science ®Google Scholar
• Batlle E, Sancho E, Francí C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2(2), 84–89 (2000).
   PubMed Web of Science ®Google Scholar
• Lin LF, Li YT, Han H et al. MicroRNA-205-5p targets the HOXD9-Snail1 axis to inhibit triple-negative breast cancer cell proliferation and chemoresistance. Aging (Albany NY) 13(3), 3945–3956 (2021).
   PubMedGoogle Scholar
• Guan X, Gu S, Yuan M et al. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial–mesenchymal transition. Oncol. Lett. 18(6), 5986–5994 (2019).
   PubMed Web of Science ®Google Scholar
• Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl. Sci. 147, 1–73 (2017).
   PubMed Web of Science ®Google Scholar
• Guo J, Luo C, Yang Y et al. MiR-491-5p, as a tumor suppressor, prevents migration and invasion of breast cancer by targeting ZNF-703 to regulate AKT/mTOR pathway. Cancer Manag. Res. 13, 403–413 (2021).
   PubMed Web of Science ®Google Scholar
• Huang WC, Chi HC, Tung SL et al. Identification of the novel tumor suppressor role of FOCAD/miR-491-5p to inhibit cancer stemness, drug resistance and metastasis via regulating RABIF/MMP signaling in triple-negative breast cancer. Cells 10(10), 2524 (2021).
   PubMed Web of Science ®Google Scholar
• Bayraktar R, Pichler M, Kanlikilicer P et al. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget 8(7), 11641–11658 (2017).
   PubMedGoogle Scholar
• Hamurcu Z, Ashour A, Kahraman N et al. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple-negative breast cancer cells. Oncotarget 7(13), 16619–16635 (2016).
   PubMedGoogle Scholar
• Tekedereli I, Alpay SN, Tavares CD et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLOS ONE 7(7), e41171 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial–mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14(4), 481–487 (2015).
   PubMed Web of Science ®Google Scholar
• Wang G, Dong Y, Liu H et al. Loss of miR-873 contributes to gemcitabine resistance in triple-negative breast cancer via targeting ZEB1. Oncol. Lett. 18(4), 3837–3844 (2019).
   PubMed Web of Science ®Google Scholar
• Pilié PG, Tang C, Mills GB et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16(2), 81–104 (2019).
   PubMed Web of Science ®Google Scholar
• Ambrosio S, Majello B. Autophagy roles in genome maintenance. Cancers (Basel) 12(7), 1793 (2020).
   PubMed Web of Science ®Google Scholar
• Chen SM, Chou WC, Hu LY et al. The effect of MicroRNA-124 overexpression on anti-tumor drug sensitivity. PLOS ONE 10(6), e0128472 (2015).
   PubMed Web of Science ®Google Scholar
• Fan YX, Dai YZ, Wang XL et al. MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 20(11), 2194–2200 (2016).
   PubMed Web of Science ®Google Scholar
• Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25(43), 5854–5863 (2006).
   PubMed Web of Science ®Google Scholar
• Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell 1(2), 117–123 (2010).
   PubMed Web of Science ®Google Scholar
• Ho JC, Chen J, Cheuk IW et al. MicroRNA-199a-3p promotes drug sensitivity in triple-negative breast cancer by down-regulation of BRCA1. Am. J. Transl. Res. 14(3), 2021–2036 (2022).
   PubMed Web of Science ®Google Scholar
• Tan X, Peng J, Fu Y et al. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 16(5), 435 (2014).
   PubMed Web of Science ®Google Scholar
• Li PP, Li RG, Huang YQ et al. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple-negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability. Aging (Albany NY) 13(21), 24171–24191 (2021).
   PubMedGoogle Scholar
• Cataldo A, Cheung DG, Balsari A et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget 7(1), 786–797 (2016).
   PubMed Web of Science ®Google Scholar
• Zhong S, Ma T, Zhang X et al. MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells. Gene 556(2), 113–118 (2015).
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012).
   PubMed Web of Science ®Google Scholar
• Xu J, Prosperi JR, Choudhury N et al. β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLOS ONE 10(2), e0117097 (2015).
   PubMed Web of Science ®Google Scholar
• Yin S, Xu L, Bonfil RD et al. Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer. Mol. Cancer Ther. 12(4), 491–498 (2013).
   PubMed Web of Science ®Google Scholar
• Li HY, Liang JL, Kuo YL et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple-negative breast cancer. Breast Cancer Res. 19(1), 133 (2017).
   PubMedGoogle Scholar
• Wu Y, Tao L, Liang J et al. miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression. Exp. Ther. Med. 20(2), 952–960 (2020).
   PubMed Web of Science ®Google Scholar
• Harrison H, Farnie G, Howell SJ et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70(2), 709–718 (2010).
   PubMed Web of Science ®Google Scholar
• Kim B, Stephen SL, Hanby AM et al. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer 15, 634 (2015).
   PubMed Web of Science ®Google Scholar
• Li ZL, Chen C, Yang Y et al. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. Int. J. Clin. Exp. Pathol. 8(5), 4378–4387 (2015).
   PubMed Web of Science ®Google Scholar
• Qiu M, Peng Q, Jiang I et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple-negative breast cancer through reduction of cancer stem cells. Cancer Lett. 328(2), 261–270 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao M, Sun B, Wang Y et al. miR-27-3p enhances the sensitivity of triple-negative breast cancer cells to the antitumor agent olaparib by targeting PSEN-1, the Catalytic subunit of Γ-secretase. Front Oncol. 11, 694491 (2021).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61–70 (2012).
   PubMed Web of Science ®Google Scholar
• Steelman LS, Navolanic PM, Sokolosky ML et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27(29), 4086–4095 (2008).
   PubMed Web of Science ®Google Scholar
• Pelicano H, Zhang W, Liu J et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 16(5), 434 (2014).
   PubMed Web of Science ®Google Scholar
• Paplomata E, O'regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther. Adv. Med. Oncol. 6(4), 154–166 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang W, Gao Z, Guan M et al. ASF1B promotes oncogenesis in lung adenocarcinoma and other cancer types. Front Oncol. 11, 731547 (2021).
   PubMedGoogle Scholar
• Wang L, Yang X, Zhou F et al. Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis. Bioengineered 13(3), 7197–7208 (2022).
   PubMed Web of Science ®Google Scholar
• Liu MM, Li Z, Han XD et al. MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in breast cancer. Sci. Rep. 7(1), 15929 (2017).
   PubMedGoogle Scholar
• Dastmalchi N, Safaralizadeh R, Hosseinpourfeizi MA et al. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation. Mol. Biol. Rep. 48(2), 1345–1357 (2021).
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch. Toxicol. 89(6), 867–882 (2015).
   PubMed Web of Science ®Google Scholar
• Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6(5), 322–327 (2005).
   PubMed Web of Science ®Google Scholar
• Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells 9(1), 198 (2020).
   PubMed Web of Science ®Google Scholar
• Loi S, Dushyanthen S, Beavis PA et al. Correction: RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin. Cancer Res. 25(4), 1437 (2019).
   PubMed Web of Science ®Google Scholar
• Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin. Cancer Res. 18(17), 4514–4521 (2012).
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-Raballand A, Cohen R et al. Targeting the TGF-β pathway for cancer therapy. Pharmacol. Ther. 147, 22–31 (2015).
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang L, He X et al. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem. Biophys. Res. Commun. 502(1), 160–165 (2018).
   PubMed Web of Science ®Google Scholar
• Bhola NE, Balko JM, Dugger TC et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 123(3), 1348–1358 (2013).
   PubMed Web of Science ®Google Scholar
• Kumar U, Hu Y, Masrour N et al. MicroRNA-495/TGF-β/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochem. Pharmacol. 192, 114692 (2021).
   PubMed Web of Science ®Google Scholar
• Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J. Pathol. 205(2), 275–292 (2005).
   PubMed Web of Science ®Google Scholar
• Shibata M, Hoque MO. Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers (Basel) 11(5), 732 (2019).
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Li X, Landis M et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl Acad. Sci. USA 106(33), 13820–13825 (2009).
   PubMed Web of Science ®Google Scholar
• Lee HE, Kim JH, Kim YJ et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br. J. Cancer 104(11), 1730–1738 (2011).
   PubMed Web of Science ®Google Scholar
• He L, Wick N, Germans SK et al. The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer. Cancers (Basel) 13(24), 6209 (2021).
   PubMed Web of Science ®Google Scholar
• Sabatier R, Charafe-Jauffret E, Pierga JY et al. Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for breast cancer. J. Clin. Med. 8(5), 612 (2019).
   PubMed Web of Science ®Google Scholar
• Nasr M, Farghaly M, Elsaba T et al. Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. Int. J. Biochem. Cell Biol. 105, 84–93 (2018).
   PubMed Web of Science ®Google Scholar
• Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl. 3), 21–26 (2008).
   PubMedGoogle Scholar
• Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5(5), 1275–1279 (2006).
   PubMed Web of Science ®Google Scholar
• Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 8(7), 790–797 (2008).
   PubMed Web of Science ®Google Scholar
• Kim H, Lin Q, Glazer PM et al. The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. Breast Cancer Res. 20(1), 16 (2018).
   PubMedGoogle Scholar
• Chouaib S, Noman MZ, Kosmatopoulos K et al. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36(4), 439–445 (2017).
   PubMed Web of Science ®Google Scholar
• Skoda AM, Simovic D, Karin V et al. The role of the Hedgehog signaling pathway in cancer: a comprehensive review. Bosn J. Basic Med. Sci. 18(1), 8–20 (2018).
   PubMed Web of Science ®Google Scholar
• Harris LG, Pannell LK, Singh S et al. Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61. Oncogene 31(28), 3370–3380 (2012).
   PubMed Web of Science ®Google Scholar
• Arnold KM, Pohlig RT, Sims-Mourtada J. Co-activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple-negative breast cancer. Oncol. Lett. 14(5), 5285–5292 (2017).
   PubMed Web of Science ®Google Scholar
• Sims-Mourtada J, Opdenaker LM, Davis J et al. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy. Mol. Carcinog. 54(11), 1480–1493 (2015).
   PubMed Web of Science ®Google Scholar
• Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell 179(5), 1033–1055 (2019).
   PubMed Web of Science ®Google Scholar
• Pan Y, Liu G, Zhou F et al. DNA methylation profiles in cancer diagnosis and therapeutics. Clin. Exp. Med. 18(1), 1–14 (2018).
   PubMed Web of Science ®Google Scholar
• Xu Q, Jiang Y, Yin Y et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell Biol. 5(1), 3–13 (2013).
   PubMed Web of Science ®Google Scholar
• Purwanto I, Heriyanto DS, Widodo I et al. MicroRNA-223 is associated with resistance towards platinum-based chemotherapy and worse prognosis in Indonesian triple-negative breast cancer patients. Breast Cancer (Dove Med. Press) 13, 1–7 (2021).
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 16(3), 203–222 (2017).
   PubMed Web of Science ®Google Scholar
• Abd-Aziz N, Kamaruzman NI, Poh CL. Development of MicroRNAs as potential therapeutics against cancer. J. Oncol. 2020, 8029721 (2020).
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15(6), 321–333 (2015).
   PubMed Web of Science ®Google Scholar
• Seto AG, Beatty X, Lynch JM et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183(3), 428–444 (2018).
   PubMed Web of Science ®Google Scholar